Neurogene Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NGNE research report →
About the company
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease).
- CEO
- Rachel L. McMinn
- IPO
- 2014
- Employees
- 107
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $558.44M
- P/E
- -7.03
- P/S
- 0.00
- P/B
- 3.32
- EV/EBITDA
- -4.65
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -37.88%
- ROIC
- -44.78%
- Revenue
- $0 · -100.00%
- Net Income
- $-90,351,000 · -20.24%
- EPS
- $-4.24 · 0.93%
- Op Income
- $-103,208,000
- FCF YoY
- -9.73%
- 52W High
- $37.27
- 52W Low
- $15.93
- 50D MA
- $29.15
- 200D MA
- $23.72
- Beta
- 1.96
- Avg Volume
- 182.99K
Get TickerSpark's AI analysis on NGNE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Cvijic Christine Mikail | sell | 739 |
| Jul 2, 26 | Cvijic Christine Mikail | sell | 2,531 |
| Jul 2, 26 | Cvijic Christine Mikail | sell | 1,530 |
| Jan 16, 24 | Woods Keith | other | 15,400 |
| Jun 14, 24 | Woods Keith | other | 7,700 |
| Jun 12, 25 | Woods Keith | other | 12,050 |
| Dec 18, 23 | Woods Keith | other | 0 |
| May 6, 26 | Cvijic Christine Mikail | sell | 4,800 |
| May 6, 26 | Cvijic Christine Mikail | sell | 4,800 |
| May 5, 26 | Shafer Christina | other | 120,000 |
Our NGNE coverage
Recent articles, reports, and earnings notes.
No research on NGNE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NGNE report →Similar companies
Peers in the same neighborhood.